Postmenopausal dyspareunia: Has the Food and Drug Administration really helped?

Menopause

Volumn 20, Issue 6, 2013, Pages 596-597

  Goldstein, Steven R ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARZOXIFENE; CENTCHROMAN; ESTROGEN; LASOFOXIFENE; OSPEMIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; DYSPAREUNIA; EDITORIAL; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; POSTMENOPAUSE; TRANSVAGINAL ECHOGRAPHY; VAGINA BLEEDING; VAGINAL DRYNESS;

DYSPAREUNIA; FEMALE; HUMANS; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; VULVA;

EID: 84879145434     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e318291ef83     Document Type: Editorial

References (11)

1. Portman DJ, Bachmann GA, Simon JA, The Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20:623-630.
2. Goldstein SR. Not all SERMs are created equal. Menopause 2006;13: 325-327.
3. Goldstein SR, Bhattoa HP, Neven P, et al. Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass. Menopause 2012;19:41-47.
4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
5. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994;170:447-451.
6. Goldstein SR, Nanavati N. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. J Obstet Gynecol 2002;187:521-527.
7. Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000;95: 95-103.
8. Kessel B, Nachtigall L, Plouffe L, Siddhanti S, Rosen A, Parsons A. Effect of raloxifene on sexual function in postmenopausal women. Climacteric 2003;6:248-256.
9. Goldstein SR, Neven P, Cummings S, et al. Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial: 5-year gynecological outcomes. Menopause 2011;18:17-22.
10. Goldstein S, Bachmann G, Lin V, Simon J, Portman D, Phelps M. Endometrial safety profile of ospemifene 60 mg when used for longterm treatment of vulvar and vaginal atrophy for up to 1 year. Climacteric 2011;14:77-77.
11. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197.